Comparative Pharmacology
Head-to-head clinical analysis: HEXALEN versus MELPHALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXALEN versus MELPHALAN.
HEXALEN vs MELPHALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Melphalan is an alkylating agent that forms interstrand crosslinks with DNA, inhibiting DNA replication and transcription, leading to cell death.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
Melphalan 0.25 mg/kg/day orally for 4 consecutive days, repeated every 4-6 weeks; or 16 mg/m² intravenously over 15-20 minutes at 2-week intervals for 4 doses.
None Documented
None Documented
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Clinical Note
moderateMelphalan + Digoxin
"Melphalan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMelphalan + Digitoxin
"Melphalan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMelphalan + Deslanoside
"Melphalan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMelphalan + Acetyldigitoxin
"Melphalan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 1.5-2 hours (IV); prolonged in renal impairment (up to 3-4 hours).
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Renal: 10-15% unchanged; hepatic metabolism (20-30%) with biliary excretion of metabolites; fecal: <5%.
Category C
Category D/X
Alkylating Agent
Alkylating Agent